WO2010019263A3 - Soluble flt constructs for treating cancers - Google Patents

Soluble flt constructs for treating cancers Download PDF

Info

Publication number
WO2010019263A3
WO2010019263A3 PCT/US2009/004665 US2009004665W WO2010019263A3 WO 2010019263 A3 WO2010019263 A3 WO 2010019263A3 US 2009004665 W US2009004665 W US 2009004665W WO 2010019263 A3 WO2010019263 A3 WO 2010019263A3
Authority
WO
WIPO (PCT)
Prior art keywords
constructs
treating cancers
soluble flt
fusion proteins
flt
Prior art date
Application number
PCT/US2009/004665
Other languages
French (fr)
Other versions
WO2010019263A2 (en
Inventor
Rebecca Bagley
Johanne Kaplan
Beverly Teicher
Jim Stefano
Clark Pan
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of WO2010019263A2 publication Critical patent/WO2010019263A2/en
Publication of WO2010019263A3 publication Critical patent/WO2010019263A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Multimeric fusion proteins of an Ig-like domain of Flt-1 linked to a multimerization domain, either directly or using a linker moiety, are useful for treating certain tumors and pathological neovascularization. The fusion proteins can be produced recombinantly and readily purified using a simple two-column procedure. The columns employ a hydrophobic charge induction resin and a ceramic hydroxyapatite resin.
PCT/US2009/004665 2008-08-15 2009-08-14 Soluble flt constructs for treating cancers WO2010019263A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8931108P 2008-08-15 2008-08-15
US61/089,311 2008-08-15
US9250508P 2008-08-28 2008-08-28
US61/092,505 2008-08-28

Publications (2)

Publication Number Publication Date
WO2010019263A2 WO2010019263A2 (en) 2010-02-18
WO2010019263A3 true WO2010019263A3 (en) 2010-08-12

Family

ID=41669536

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/004665 WO2010019263A2 (en) 2008-08-15 2009-08-14 Soluble flt constructs for treating cancers

Country Status (2)

Country Link
AR (1) AR073078A1 (en)
WO (1) WO2010019263A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005021811D1 (en) 2004-09-13 2010-07-22 Genzyme Corp MULTI-MORE CONSTRUCTS
HUE035554T2 (en) * 2010-08-06 2018-05-02 Genzyme Corp Vegf antagonist compositions and uses thereof
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
AU2014212640B2 (en) 2013-01-30 2017-10-19 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
ES2883158T3 (en) 2014-07-30 2021-12-07 Ngm Biopharmaceuticals Inc Compositions and procedures for use for the treatment of metabolic disorders
KR20170074852A (en) * 2014-10-31 2017-06-30 엔지엠 바이오파마슈티컬스, 아이엔씨. Compositions and methods of use for treating metabolic disorders
SG11201807279QA (en) 2016-03-31 2018-09-27 Ngm Biopharmaceuticals Inc Binding proteins and methods of use thereof
KR101685532B1 (en) * 2016-04-26 2016-12-13 한국프라임제약주식회사 A VEGFR fusion protein
WO2019219048A1 (en) * 2018-05-18 2019-11-21 北京辅仁瑞辉生物医药研究院有限公司 Fused polypeptide conjugate having extended half-life period

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017977A1 (en) * 1999-06-08 2003-01-23 Yuping Xia Methods of treating inflammatory skin diseases
US20040198957A1 (en) * 2001-08-27 2004-10-07 Inna Way Method for removing endotoxins from protein solutions
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017977A1 (en) * 1999-06-08 2003-01-23 Yuping Xia Methods of treating inflammatory skin diseases
US20040198957A1 (en) * 2001-08-27 2004-10-07 Inna Way Method for removing endotoxins from protein solutions
US20070224178A1 (en) * 2004-09-13 2007-09-27 Abraham Scaria Multimeric constructs
US20060115876A1 (en) * 2004-11-12 2006-06-01 Bayer Healthcare Llc Site-directed modification of FVIII

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FISCHER ET AL.: "Anti-PIGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels.", CELL, vol. 131, 2 November 2007 (2007-11-02), pages 463 - 475 *
GAGNON ET AL.: "A Ceramic Hydroxyapatite? Based Purification Platform Simultaneous Removal of Leached Protein A, Aggregates, DNA, and Endotoxins from MAbs.", BIOPROCESS INTERNATIONAL., February 2006 (2006-02-01), pages 50 - 56, Retrieved from the Internet <URL:www.validated.com/revalbio/pdffiles/bpicht.pdf> [retrieved on 20100524] *

Also Published As

Publication number Publication date
AR073078A1 (en) 2010-10-13
WO2010019263A2 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
WO2010019263A3 (en) Soluble flt constructs for treating cancers
IN2012DN00640A (en)
WO2011036564A3 (en) Hyperblebbing shigella strains
EP3144322A3 (en) Bispecific binding molecules binding to vegf and ang2
WO2010027827A3 (en) Targeted costimulatory polypeptides and methods of use to treat cancer
UA107490C2 (en) TNF-a-BINDING PROTEINS
WO2010118169A3 (en) Human protein scaffold with controlled serum pharmacokinetics
AU2012328921A8 (en) Immunobinders directed against TNF
AU2010310545A8 (en) Anti-GCC antibody molecules and related compositions and methods
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
WO2010066803A3 (en) Human antibodies against human tissue factor
NZ700891A (en) 4-1bb binding molecules
MX2011008752A (en) Improved anti-serum albumin binding variants.
EP3539988A3 (en) Monoclonal antibodies against her2
EP3578568A3 (en) Cxcr2 binding polypeptides
WO2010020766A3 (en) Interleukin fusion polypeptides
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
MX2013002379A (en) Vegf-binding molecules.
EP3656788A3 (en) Improved anti-serum albumin binding variants
WO2011031477A3 (en) Nucleolin-binding peptides, nucleolin-binding lytic peptides, fusion constructs and methods of making and using same
WO2009150547A3 (en) 2-pyridyl substituted imidazoles as alk4 and/or alk4 inhibitors
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
PH12013502031A1 (en) BISPECIFIC BINDING MOLECULES BINDING TO D114 AND Ang2
IL209455A0 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
WO2011040973A3 (en) Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09806983

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09806983

Country of ref document: EP

Kind code of ref document: A2